The economics of HIV/AIDS
Piar, M.; Pérez-Nieves, R.; Franjul, R.; Amill, S.A.
Boletin de la Asociacion Medica de Puerto Rico 91(1-6): 64-71
1999
ISSN/ISBN: 0004-4849 Document Number: 703023
Since the Acquired Immunodeficiency Syndrome (AIDS) was discovered, effort have been mostly directed toward the epidemiologic and clinical characteristics of the condition. More recentlly, interest has been placed in the economic impact of the pandemic. Both rich and poor countries have been affected, imposing exponential increases in health care costs. The availability of much more effective drug regimens brings another dimensions in costs, as it not only represents more costly pharmacotherapy but a longer life span, need for costly laboratory monitoring, and the eventual cost of treating the inevitable terminal spectrum of complications. On the other hand, nobody questions that the benefit of additional disease free years, a better quality of life, and a longer life span are worth the costs. Poor countries still struggle to provide the former standard therapy and, in many cases, the more effective regimens are just unaffordable. We present an overviezv of AIDS-related economic issues in the World, in the United States, and Puerto Rico.
Document emailed within 1 workday
